It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Background
Agitation is a challenging neuropsychiatric symptom (NPS) of Alzheimer's disease (AD). A crossover trial found that nabilone significantly improved agitation in AD patients over 6 weeks compared to placebo. Here, we aim to identify a combination of biomarkers that could be used to predict treatment response to nabilone for AD‐associated agitation.
Methods
Agitation was assessed using the Cohen‐Mansfield Agitation Inventory (CMAI). Serum concentrations of 13 markers were measured. Linear regression was used to estimate change in CMAI due to nabilone for the high and low groups of each biomarker. Biomarkers with a difference ≥8.5 points between groups were included in subsequent multivariate models. Index scores representing the difference between expected CMAI change given nabilone and placebo were calculated and divided into quartiles. Mean difference in CMAI change and 95% confidence intervals were estimated via bootstrapping.
Results
Four of the 13 biomarkers which met criteria specified above were included in multivariate modeling (n = 67). Nabilone was more efficacious in participants with higher IL‐6 (estimated change in CMAI ‐15.4, standard error (SE) 5.6), higher ISO‐8 (‐14.4, SE=5.0), higher 24S‐OHC (‐14.2, SE=4.1), and lower clusterin (‐14.6, SE=4.4). Participants in Q1 of index scores demonstrated better response to nabilone with a mean difference in CMAI change of ‐20.9 (95% CI: ‐31.8, ‐9.2), while those in Q2‐4 showed no difference between treatments.
Conclusions
Participants with higher levels of inflammation, oxidative stress, and cholesterol metabolite were more likely to benefit from nabilone for agitation in AD. A combination of biomarkers could help in distinguishing responders and non‐responders to nabilone.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Sunnybrook Research Institute, Toronto, ON, Canada,, University of Toronto, Toronto, ON, Canada,
2 Sunnybrook Research Institute, Toronto, ON, Canada,
3 Sunnybrook Research Institute, Toronto, ON, Canada,, University of Toronto, Toronto, ON, Canada,, Sunnybrook Health Sciences Centre, Toronto, ON, Canada,
4 University of Toronto, Toronto, ON, Canada,, Center for Addiction and Mental Health, Toronto, ON, Canada,
5 Sunnybrook Research Institute, Toronto, ON, Canada,, Sunnybrook Health Sciences Centre, Toronto, ON, Canada,, Department of Psychiatry, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada,
6 Baycrest Hospital, Toronto, ON, Canada,